Insider Selling: Adaptive Biotechnologies (NASDAQ:ADPT) COO Sells 30,941 Shares of Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 30,941 shares of the stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $16.00, for a total value of $495,056.00. Following the sale, the chief operating officer owned 575,235 shares of the company’s stock, valued at approximately $9,203,760. This represents a 5.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link.

Julie Rubinstein also recently made the following trade(s):

• On Tuesday, March 3rd, Julie Rubinstein sold 30,941 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $15.67, for a total value of $484,845.47.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT traded down $0.51 during trading hours on Thursday, hitting $15.93. 1,850,817 shares of the company’s stock were exchanged, compared to its average volume of 1,676,883. The company’s 50-day moving average price is $16.83 and its 200-day moving average price is $15.79. Adaptive Biotechnologies Corporation has a 1-year low of $6.26 and a 1-year high of $20.76. The stock has a market capitalization of $2.45 billion, a price-to-earnings ratio of -39.82 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The company had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same period in the previous year, the business posted ($0.23) EPS. The company’s revenue for the quarter was up 51.0% on a year-over-year basis. On average, research analysts expect that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Adaptive Biotechnologies News Roundup

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results and revenue beat — Adaptive reported stronger-than-expected Q4 results (EPS beat and revenue +51% YoY), which supports longer-term growth expectations and was a catalyst for bullish analyst notes earlier this quarter. MarketBeat ADPT page
• Positive Sentiment: Analyst backdrop mostly constructive — Multiple firms have buy/overweight ratings and recent price-target increases (consensus “Moderate Buy”), which provides support vs. headline volatility. Analyst coverage summary
• Neutral Sentiment: Short-interest data shows an anomalous 0-share reading and a 0.0 days-to-cover metric — this appears to be a data/reporting artifact rather than a meaningful change in bearish positioning. (No actionable signal until corrected data is posted.)
• Neutral Sentiment: Small institutional activity — several modest new or increased stakes were reported in recent filings; institutional ownership remains high (~99%). These moves are small relative to market cap and unlikely to drive intraday price action. Institutional holdings
• Negative Sentiment: Large CEO selling — CEO Chad Robins has executed multiple large sales, including a 289,024?share sale on Mar. 2 at ~$15.82 (~$4.57M) and other recent disposals totaling hundreds of thousands of shares; these sizable reductions (one filing showed a ~12.7% position cut) are a near-term negative signal for investor sentiment. CEO sale SEC filing
• Negative Sentiment: Other insider sales — COO Julie Rubinstein sold ~30.9k shares (filings show sales at ~$15.67–$16.00 for ~$485k–$495k), and director/insider Harlan Robins sold multiple blocks (10k and ~14.2k shares). Multiple insider sales in a short window amplify market concern about near-term insider conviction. COO sale SEC filing Harlan sale SEC filing

Wall Street Analysts Forecast Growth

ADPT has been the topic of a number of recent research reports. Wall Street Zen upgraded shares of Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Piper Sandler set a $21.00 price objective on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. BTIG Research raised their target price on Adaptive Biotechnologies from $21.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. upped their price objective on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an “overweight” rating in a research report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $18.25.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. AQR Capital Management LLC boosted its holdings in shares of Adaptive Biotechnologies by 45.8% during the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after acquiring an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after buying an additional 2,914 shares in the last quarter. Caxton Associates LLP acquired a new position in shares of Adaptive Biotechnologies in the first quarter valued at about $93,000. Envestnet Asset Management Inc. bought a new position in shares of Adaptive Biotechnologies during the second quarter worth approximately $467,000. Finally, Versor Investments LP acquired a new stake in Adaptive Biotechnologies during the second quarter worth approximately $367,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.